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ABSTRACT
 
Purpose: The aim of our study is to evaluate the efficacy and safety of ATOMS® system 
for the treatment of postoperative male stress urinary incontinence (SUI).
Materials and methods: We retrospectively evaluated all patients treated at our insti-
tution for postoperative male SUI with ATOMS® implant. We excluded patients with 
low bladder compliance (< 20 mL / cmH2O), uncontrolled detrusor overactivity, detru-
sor underactivity (BCI < 100), urethral or bladder neck stricture and low cystometric 
capacity (< 200 mL).
Results: From October 2014 to July 2017 we treated 52 patients, mean age 73.6 years. 
Most of them (92.3%) had undergone radical prostatectomy, 3.85% simple open pros-
tatectomy, 3.85% TURP; 28.8% of patients had undergone urethral surgery, 11.5% ad-
juvant radiotherapy; 57.7% had already undergone surgical treatment for urinary in-
continence. The average24 hours pad test was 411.6 g (180 - 1100). The mean follow-up 
was 20.1 months (8.1 - 41.5) 30.8% of patients were dry, 59.6% improved ≥ 50%, 7.7% 
improved < 50% and 1.9% unchanged. In total 73.1% reached social continence. There 
was a significant reduction of the 24 hours pad test and ICIQ - UI SF scores (p < 0.01).
In the postoperative follow-up we detected complications in 8 patients (19%): 5 cases 
of displacement of the scrotal port, in 2 cases catheterization difficulties, one case of 
epididimitis and concomitant superficial wound infection;  no prosthesis infection, nor 
explants.
Radiotherapy, previous urethral surgery,previous incontinence surgery were not statis-
tically related to social continence rates (p 0.65;p 0.11;p 0.11).
Conclusions: The ATOMS® system is an effective and safe surgical treatment of mild 
and moderate male postoperative SUI with durable results in the short term.
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INTRODUCTION
Radical prostatectomy (RP) is considered 
the main cause of male stress urinary inconti-
nence (SUI) with variable incidence between 4% 
and 40% (1, 2). The main predictive factors for 
postoperative stress incontinence are age, body 
mass index, comorbidity index, presence of low 
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urinary tract symptoms (LUTS), prostate volume 
and surgeon expertise (2, 3). Surgical treatment of 
benign prostatic hyperplasia (BPH) has a lower 
incidence of postoperative SUI, ranging between 
1.9 - 2.2% (4). Most patients are offered pelvic 
floor muscle exercise , that improves early con-
tinence rates but not long term continence rates 
(5). When conservative treatments have failed, 
patients are usually offered surgical treatments 
after stabilization at 12 - 18 months. The arti-
ficial urinary sphincter (AUS) is still considered 
the gold standard for the treatment of male SUI 
with dry rates up to 86% (6), but high costs, 
postoperative complication and re - operation 
rates of the artificial urinary sphincter (AUS) 
led to the development of alternative systems. 
The continence results of sling systems vary 
around 50%, depending on the definition for 
therapeutic success (7). Most slings are not ad-
justable and some can be adjusted after implan-
tation only with a small surgical procedure. The 
ATOMS® system was created to overcome this 
issues and was introduced in Europe in 2008. 
It is an extra urethral bulking system in form 
of a hydraulic sphincter cushion support made 
of three parts: two polypropylene mesh arms, a 
cushion and a titanium port. Compression can 
be modulated with office - based filling pro-
cedures. Unlike the artificial sphincter, which 
encircles the urethra circumferentially by inter-
fering with venous blood flow and predisposing 
the urethra to atrophy and erosion, the ATOMS® 
system only compresses the ventral portion of 
the urethra, leaving the dorsal and lateral blood 
flow intact (7, 8).
 The aim of this work is to evaluate mid - 
term efficacy and safety of ATOMS® system for 
the treatment of postoperative male SUI.
MATERIALS AND METHODS
 This retrospective study was conduc-
ted between October 2014 and July 2017. We 
enrolled all consecutive ATOMS® implants at 
our center. All patients were clinically diagno-
sed with non - neurogenic postoperative stress 
urinary incontinence. Before surgical treatment 
each patient underwent anamnestic data collec-
tion, 24 hours pad test and pad count, physical 
examination, urodynamic evaluation, ICIQ - UI 
SF questionnaire. We evaluated the severity of 
urinary incontinence referring to the 24 hours 
pad test: no incontinence (0 pads / day), mild 
incontinence (< 200 g / day), moderate inconti-
nence (200 - 400 g / day), severe incontinence (> 
400 g / day). We excluded and did not implant 
patients with low bladder compliance (< 20 mL / 
cmH2O), uncontrolled detrusor overactivity (DO), 
detrusor underactivity (BCI < 100), urethral or 
bladder neck stricture and low cystometric ca-
pacity (< 200 mL). All patients were implanted 
with ATOMS® system by a single surgeon. Pa-
tients were followed up with a first clinical visit 
at 1 month after the intervention and the device 
was refilled in cases of persistent stress urinary 
incontinence. There was not a fixed schedule for 
subsequent follow-up visit. At the last follow-
-up, all patients underwent a follow-up physical 
examination, 24 hours pad test and pad count, 
ICIQ - UI SF and PGI - I questionnaire. The pri-
mary objective of this study was to evaluate the 
efficacy, safety and patient satisfaction of the 
ATOMS® system from the last follow-up.
Statstical analysis
 The population has been described throu-
gh descriptive analyses. For numerical variables, 
mean, median, minimum and maximum values, 
SD, IQR have been calculated. The normality of 
the distribution has been checked with the Kol-
mogorov - Smirnov test. As numerical variables 
were not normally distributed, we considered 
median ± intrerquartile range and we applied 
non parametric tests. For categorical variables 
have been calculated absolute and relative fre-
quency distributions and double entry tables 
have been created. To evaluate the relationship 
between categorical variables, we applied Fisher 
exact test, being the size of some cells less than 
5. To evaluate the relationship between outcome 
and predictors, we applied the calculation of 95% 
RR. The non parametric Wilcoxon Signed Ranks 
test for paired samples has been used to compare 
pre and post operative numerical non - normally 
distributed variables. All statistical analyses were 
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performed using R 3.4.2 software. The significan-
ce level was set at 0.05.
SURGICAL TECHNIQUE
The ATOMS® system implant is fully stan-
dardized and facilitated by the single - piece con-
figuration of the device. The patient is positioned 
in a lithotomy position with excellent perineum 
exposure and adequate flexion of the hips. A 14 
French urethral catheter is positioned. After a ver-
tical incision of 4 - 5 cm, the dissection plan is 
prepared until fibers of the bulbospongious muscle 
are encountered, maintaining them intact. Late-
rally the dissection plane follows the muscle fibers 
until the base of the crura. To reduce postoperative 
pain, it is important to avoid damaging the poste-
rior scrotal nerves (Figure-1). A good preparation 
of the ischiorectal fossa is important for the place-
ment of the implant fixation arms. With a specific 
curved tunneller, the arms of the sling are positio-
ned bilaterally with an outside - in transobturator 
passage (Figure-2). Then the silicon cushion is fi-
xed to the arms with two non - absorbable mono-
filament sutures. After removing the air present in 
the system, it is filled with saline solution until re-
aching ambient pressure (Figure-3). Depending on 
the degree of incontinence and detrusor contrac-
tility, the system can be filled further with one mL 
Figure 1 - Dissection plan prepared until fibers of the 
bulbospongious muscle are encountered; lateral dissection 
plane evidencing the base of the crura.
Figure 2 - Outside-in transobturator passage of the arms 
with a specific tunneler.
of saline solution. Finally, a dartos scrotal pouch 
is created to accommodate the port (Figure-4). A 
double - layer suturing closure guarantees a low 
risk of infection and extrusion of the device. There 
is no need, according to standardized technique, 
to place any drainage.
RESULTS
We treated 52 male patients with ATOMS® 
system. The average age was 73.6 years (median 
73.7, range 58.9 - 84.3). In this population, 44 
(84.6%) patients had undergone open radical open 
prostatectomy, 3 (5.8%) laparoscopic radical pros-
tatectomy, 1 robot - assisted radical prostatectomy 
(1.9%), 2 (3.85%) patients transvesical simple open 
prostatectomy and 2 (3.85%) transurethral resec-
tion of the prostate (TURP). The average interval 
between the intervention and ATOMS® implant was 
6.84 years on average (range 1.41 - 16.77). Among 
the patients who underwent radical prostatectomy, 
42 (80.8%) had a bilateral nerve - sparing (NS) pro-
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cedure and 4 (7.7%) an unilateral NS procedure; 8 
had undergone urethrotomy for an urethral stric-
ture, 7 had undergone vesicoureteral anastomosis 
resection; at pathology report all patients were 
diagnosed with prostate adenocarcinoma, clinical 
and pathological stage are reported in Table-1. Six 
patients had undergone adjuvant radiotherapy, 5 
were on hormone therapy with LHRH analogue / 
LHRH antagonist. All patients were in complete 
remission from cancer disease, in cases of radi-
cal prostatectomy with undetectable PSA. Preo-
perative urodynamic testing demonstrated in all 
patients a good bladder compliance (> 20 cmH2O 
/ mL), absence of DO and the presence of uro-
dynamic stress urinary incontinence with mean 
VLPP 64.79 cmH2O (median 62.5, range 32 - 105). 
The average 24 hours pad test was 411.6 g (me-
dian 370, range 180 - 1100 g).The average number 
of pads used was 4.23 (median 4, range 2 - 8) 3 
patients (5.8%) were suffering from mild inconti-
nence, 40 patients (76.9%) moderate incontinen-
ce, 9 patients (17.3%) severe incontinence. Thirty 
patients (57.7%) had already undergone surgical 
treatment for urinary incontinence: in 26 cases a 
ProACT device, in one case an artificial sphincter 
(FlowSecure), in two cases both a ProACT device 
then an artificial sphincter (AMS800), in one case 
both an intraurethral bulking therapy and subse-
Figure 3 - Position of the cushion after fixation of the arms; filling of the cushion with saline solution.
Figure 4 - Dartos scrotal pouch that accommodates the port; refill at clinical visit.
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quently a ProACT. Nineteen patients had under-
gone pelvic floor rehabilitation. Thirteen patients 
were treated with antimuscarinic oral therapy for 
OAB syndrome, without evidence of DO at preo-
perative urodynamic testing; 11 patients were tre-
ated with duloxetine without sustainable results.
The average surgical time was 51.0 minu-
tes (median 49, range 40 - 84).The mean follow-up 
was 22.1 months (median 20.7, range 8.1 - 41.5). 
One patient was lost at follow-up. The average 
number of fillings was 1.55 (median 1, range 0 
- 8) with an average filling volume of 10.7 mL 
(median 9, range 0 - 28). In the immediate posto-
perative time, there were no severe complications 
(Clavien - Dindo ≥ 2), only 6 cases of scrotal pain 
and numbness persisting at 4 weeks after implant, 
solved with oral anti - inflammatory therapy, and 
2 cases of acute postoperative retention, treated 
with temporary deflate of the cushion.
Table 1 - Clinical and pathological stage.
Clinical stage Patients
cT1c N0/Nx M0 38 (73.1%)
cT2a N0/Nx M0 8 (15,4%)
cT2b N0/Nx M0 3 (5.8%)
cT2c N0/Nx M0 1 (1.9%)
cT3b N0/Nx M0 2 (3.8%)
Patological stage Patients
pT2a N0 M0 14 (26.9%)
pT2b N0 M0 20 (38.5%)
pT2c N0 M0 8 (15.4%)
pT3a N0 M0 5 (9.6%)
pT3b N0 M0 4 (7.7%)
pT3b N1 M0 1 (1.9%)
Pathological Gleason score Patients 
Gleson 6 22 (42.3%)
Gleason 7 (3+4) 18 (34.6%)
Gleason 7 (4+3) 10 (19.2%)
Gleason 8 2 (3.9%)
In the postoperative follow-up we detec-
ted complications in 8 patients (19%): 5 cases of 
displacement of the scrotal port (with surgical re-
placement in all cases), in 2 cases catheterization 
difficulties and difficulty to deflate the device, one 
case of epididimitis and concomitant superficial 
wound infection, treated with prolonged antibio-
tic therapy. There has been no prosthesis infection, 
nor explantations.
At the last follow-up available, 16 patients 
(30.8%) were completely dry, 31 (59.6%) improved 
≥ 50%, 4 (7.7%) improved < 50% and 1 (1.9%) did 
not change. In total 38 patients (73.1%, ) reached 
social continence (use of 0 or 1 security pad / day) 
(Table-2) (all p < 0.05, Fisher’s exact test). We had 
a significant reduction of the 24 hours pad test 
(mean 100.3 g; median 87.5, range 440 - 0; p < 
0.01 Wilcoxon signed ranks test).
We had postoperative urodynamic data on 
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20 (38.5%) patients demonstrating in all of them 
a good bladder compliance (> 20 cmH2O / mL), 
absence of DO and significant bladder outlet obs-
truction (BOOI > 40). All patients evaluated had 
reached social continence and had no leakeage 
during urodynamic testing.
Taking into account the degree of preope-
rative incontinence, all patients (n = 3) with mild 
incontinence were dry. In patients with modera-
te incontinence (n = 40), 12 (30%) were dry, 23 
(57.5%) improved ≥ 50%, 4 (10%) improved < 50% 
and only 1 (2.5%) unchanged; a total of 30 pa-
tients (75%) reached social continence. In patients 
with severe incontinence (n = 9), one (11.1%) was 
dry, 8 (88.9%) improved ≥ 50%; 5 patients (55.5%) 
achieved social continence (all p < 0.05 Fisher’s 
exact test). Patients with mild incontinence had 
a 3.76 (95% CI 2.37 - 6) higher probability to be 
dry if compared to those with moderate and severe 
incontinence (p - value 0.03, Fisher’s exact test).
In the subpopulation of patients with his-
tory of radiation treatment, 2 (33.3%) were dry, 3 
(50%) were improved ≥ 50% and 1 (16.7%) had 
improved < 50%. A total of 4 patients (66.7%) 
reached social continence (all p < 0.05 Fisher’s 
exact test). In the subpopulation of patients who 
have previously undergone surgical treatment 
for incontinence, 4 (13.3%) were dry, 23 (76.7%) 
improved ≥ 50%, 2 (6.7%) improved < 50%, and 
one (3.3%) was unchanged. In total, 19 patients 
(63.3%) reached social continence (all p < 0.05 
Fisher’s exact test). In the subpopulation of pa-
tients with previous urethral surgery, 2 (13.3%) 
were dry, 12 (80%) were improved ≥ 50% and 1 
(6.7%) had improved < 50%. A total of 10 patients 
(66.7%) reached social continence (p < 0.01) (ima-
ge 5) (all p < 0.05 Fisher’s exact test).
Patients who underwent previous urethral 
surgery or previous incontinence surgery have a 
65% lower probability to be dry if compared to 
patients without previous urethral or incontinen-
ce surgery (p - values < 0.05 and < 0.01, Fisher’s 
exact test); they have a 2.23 higher probability to 
be > 50% improved without being dry (p - values 
< 0.05 and < 0.01, Fisher’s exact test).
The average results of the quality of life 
questionnaire ICIQ - UI SF were 15.96 (median 16, 
range 12 - 20) before treatment and 7.7 (median 8, 
range 0 - 15) at the last follow-up, with a statisti-
cally significant variation (p < 0.01 Wilcoxon sig-
ned ranks test) (Table-3). The questionnaire on the 
subjective satisfaction of continence results (PGI 
- I) showed that 25 (49%) patients reported being 
very much improved, 17 (33.3%) much improved, 
9 (17.6%) slightly improved; it is noteworthy that 
no patient expressed a negative subjective judg-
ment towards treatment.
DISCUSSION
The results of our study, after a mean follow-
-up of 22.1 months, showed that 30.8% of patients 
were completely dry and 59.6% reduced losses > 
50%: in total 73.1% reached social continence. The-
Table 2 - Continence results in global and specific populations.
Dry Improved 
>50%
Improved 
<50%
Unchanged Social 
continence
Substantial 
benefit (>50%)
Global population (52) 16 (30.8%) 31 (59.6%) 4 (7.7%) 1 (1.9%) 38  (73.1%) 39 (75%) (p < 0.05)
Mild incontinence (3) 3 (100%) - - - 3 (100%) 3 (100%) (p < 0.05)
Moderate incontinence (40) 12 (30%) 23 (57.5%) 4 (10%) 1 (2.5%) 30  (75%) 35 (87.5%) (p < 0.05)
Severe incontinence (9) 1 (11.1%) 8 (88.9%) - - 5 (55.5%) 9 (100%) (p < 0.05)
Radiotreated patients (6) 2 (33.3%) 3 (50%) 1 (16.7%) - 4 (66.7%) 5 (83,3%) (p < 0,05)
Previous surgery for SUI (30) 4 (13.3%) 23 (76.7%) 2 (6.7%) 1 (3.3%) 19  (63.3%) 27 (90%) (p < 0.05)
Previous urethral surgery (15) 2 (13.3%) 12 (80%) 1 (6.7%) - 10 (66.7%) 14 (93.3%) (p < 0.05)
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Table 3 - Preoperative and postoperative ICIQ-SF 
questionnaire results.
Preoperative ICIQ-UI Postoperative ICIQ-UI
17 6
17 13
16 7
17 7
14 9
18 13
16 11
20 9
15 9
15 10
16 11
17 7
15 8
17 12
15 8
19 8
16 12
15 8
14 7
16 7
16 0
14 9
19 15
19 9
19 0
15 6
16 9
15 0
15 9
15 0
15 0
17 10
14 6
15 7
17 9
17 6
16 7
12 9
18 9
15 11
15 5
15 5
13 10
17 7
15 8
16 11
18 8
15 1
15 11
15 8
16 6
Continuation
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se data are in line with published literature, although 
there are extremely variable results and definitions 
of continence; the results of dry rates vary from 
92.3% of Gonzalez et al. on a small group of 13 pa-
tients (9), to 38.9% of Krause et al. (10). If we con-
sider a substantial benefit (> 50%), we find values 
between 62.2% and 92.3%, confirming the validity 
of our results (10-14). Three studies have shown a 
significant reduction in ICIQ - SF score, as evidenced 
by our study (10, 14, 15).
 The average operative time  in our popu-
lation was 51 minutes, in line with other literature 
studies (range 44 - 67.6) (9-15). The average num-
ber of device refillings was 1.55 with an average 
filling volume of 10.7 mL; other studies in litera-
ture show a greater number of refillings (range 1 
- 4.5) and a higher average total cushion volume 
(17.5 - 18 mL) (11-14).
All studies in literature evidence a higher 
incidence of postoperative scrotal pain and pares-
thesiae (23.1 - 68.7%) (9, 11, 13, 15). Mühlstädt et 
al. showed a lower incidence of 5.6%, as they con-
sidered the persistence of scrotal pain 4 weeks after 
intervention (14). Using the same definition, in our 
series only 6 patients (11.5%) experienced scrotal 
pain and numbness. In our cohort we had a single 
case of superficial wound infection (2.3%), whereas 
in the literature the incidence of wound infection is 
variable between 4% and 19.4%, with rates of device 
explant for deep infection between 4% - 30.6%. This 
difference can be partially explained by the inclu-
sion in previous studies of first - generation devices 
(9, 12-14). A careful preoperative perineal brushing 
with disinfectant solution, execution of hair removal 
before entering the operative room, adequate anti-
biotic prophylaxis with cephalosporins and a sur-
gical technique that guarantees absolute sterility of 
procedures, have so far prevented from deep pros-
thesis infection requiring removal.
The most common complication encoun-
tered was port displacement (9.6%) resulting in 
the impossibility of modulating the filling of the 
cushion, requiring a surgical revision. In literatu-
re, Mühlstädt et al. indicate a rate of port erosion 
of 5.6%, but does not include cases of port displa-
cement without surface erosion (14).
Results obtained by patients who underwent 
RT, urethral surgery or previous incontinence sur-
gery, were slightly lower than the overall popula-
tion. For the population of patients previously tre-
ated for incontinence, we have shown a significant 
reduction in the dry rate but not of the social con-
tinence. The reduced dry rate in patients who un-
derwent previous urethral or incontinence surgery 
is balanced by a higher probability to have a > 50% 
improvement without being dry. These data suggest 
that ATOMS® is not contraindicated in such com-
plicated cases. Mühlstädt et al. also showed that RT 
patients achieved slightly worse continence results, 
but without any statistical significance (14). Accor-
ding to our results, we believe that the ATOMS® 
system can be considered a first and second line 
surgical treatment for mild to moderate male SUI.
A study on the impact of ATOMS® on the 
patient’s sexual life showed a significant incre-
ase in the IEEF - 5 questionnaire values (16). In 
our study, the impact on the patient’s sex life has 
not been directly analyzed, but we can hypothesi-
ze that overall improvement in the quality of life 
reported may also have a positive impact on the 
patient’s sexual life.
One of the risks related to AUS is the deve-
lopment of urethral atrophy, that occurs on avera-
ge in 7.9% of cases (1.9-28.6%) and appears to be 
linked to tissue hypoxia and previous radiotherapy. 
To reduce this possible complication, the ATOMS® 
system is characterized by a non circumferential 
compression. Another possible complication, al-
though rare, of the AUS is a mechanical failure in 
one component due to the complexity of the sys-
tem, with rates varying from 2.0% to 13.8% (6). The 
lack of mechanical parts and the single - compo-
nent built of the ATOMS® system may thus repre-
sent an advantage, but we need a longer follow-up 
to confirm this hypothesis.
A comparative study of Chung et al. betwe-
en adjustable slings (Argus) and non - adjustable 
slings (Advance) showed that social continence re-
sults are comparable (92% vs. 84%, p=0.45); howe-
ver, when patients were left free to choose between 
the two devices, there was a tendency to choose the 
adjustable sling (57%) for the possibility of posto-
perative tensioning with a surgical procedure (17). 
A1ccording to international Guidelines, non - ad-
justable slings have consolidated indications, such 
as patients with moderate incontinence, non - ir-
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radiated, and with positive repositioning test. The 
advantage of ATOMS® system is the office - based 
modulability, without surgical procedures, and the 
possibility to treat complex cases that are generally 
excluded by other slings.
We believe that this study has several streng-
ths: the size of the cohort, an adequate follow-up, 
single surgeon interventions, the use of objective 
validated questionnaires. The main limitations of 
this study include the retrospective nature of the 
study, the lack of postoperative uorodynamic data 
for all patients, the lack of standardized follow-up 
visit schedule.
CONCLUSIONS
In our experience the ATOMS® system is 
an effective and safe surgical treatment of non - 
neurogenic male SUI. The results are good and are 
maintained in the follow-up. This system appears 
to be innovative for some unique characteristics: 
outpatient modulability and a single - incision 
transobturator technique. The implant is not con-
traindicated in patients who underwent urethral 
surgery and previous incontinence surgery.
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